GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Duopharma Biotech Bhd (XKLS:7148) » Definitions » ROC %

Duopharma Biotech Bhd (XKLS:7148) ROC % : 5.29% (As of Sep. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Duopharma Biotech Bhd ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Duopharma Biotech Bhd's annualized return on capital (ROC %) for the quarter that ended in Sep. 2023 was 5.29%.

As of today (2024-04-27), Duopharma Biotech Bhd's WACC % is 7.32%. Duopharma Biotech Bhd's ROC % is 7.35% (calculated using TTM income statement data). Duopharma Biotech Bhd generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Duopharma Biotech Bhd ROC % Historical Data

The historical data trend for Duopharma Biotech Bhd's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Duopharma Biotech Bhd ROC % Chart

Duopharma Biotech Bhd Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.80 8.59 7.87 7.79 7.89

Duopharma Biotech Bhd Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.16 7.51 9.91 6.36 5.29

Duopharma Biotech Bhd ROC % Calculation

Duopharma Biotech Bhd's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2022 is calculated as:

ROC % (A: Dec. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2021 ) + Invested Capital (A: Dec. 2022 ))/ count )
=92.42 * ( 1 - 17.37% )/( (960.604 + 975.235)/ 2 )
=76.366646/967.9195
=7.89 %

where

Invested Capital(A: Dec. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1164.131 - 65.547 - ( 137.98 - max(0, 230.309 - 494.796+137.98))
=960.604

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1221.919 - 89.047 - ( 157.637 - max(0, 264.591 - 541.487+157.637))
=975.235

Duopharma Biotech Bhd's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2023 is calculated as:

ROC % (Q: Sep. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Sep. 2023 ))/ count )
=66.772 * ( 1 - 21.5% )/( (985.494 + 995.707)/ 2 )
=52.41602/990.6005
=5.29 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1248.792 - 127.733 - ( 135.565 - max(0, 290.407 - 575.987+135.565))
=985.494

Invested Capital(Q: Sep. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1383.502 - 105.911 - ( 281.884 - max(0, 333.065 - 716.548+281.884))
=995.707

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Duopharma Biotech Bhd  (XKLS:7148) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Duopharma Biotech Bhd's WACC % is 7.32%. Duopharma Biotech Bhd's ROC % is 7.35% (calculated using TTM income statement data). Duopharma Biotech Bhd generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Duopharma Biotech Bhd ROC % Related Terms

Thank you for viewing the detailed overview of Duopharma Biotech Bhd's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Duopharma Biotech Bhd (XKLS:7148) Business Description

Traded in Other Exchanges
N/A
Address
Lot 2599, Jalan Seruling 59, Kawasan 3, Taman Klang Jaya, Klang, MYS, 41200
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. It develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer and exporter of pharmaceutical products and medicines.

Duopharma Biotech Bhd (XKLS:7148) Headlines

No Headlines